NEW YORK, Dec. 22, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 12^th Annual LifeSci Partners Corporate Access Event, to be held in San Francisco, California on January 9-11^th, 2023.

"We are delighted to participate in this annual event once again and excited to see that it is in-person this year," said Raj Mehra, Ph.D., Chairman and CEO of Seelos. "We have a lot to discuss this year, including the registrational studies in acute suicidal ideation and behavior in major depressive disorder, amyotrophic lateral sclerosis and spinocerebellar ataxia, plus recently presented preclinical data in Huntington's and Parkinson's diseases from our R&D event."

For information and registration: https://lifescievents.com/event/12th-annual-lifesci-partners-corporate-access-event/

Replay of the Seelos R&D Update Webcast: https://seelostherapeutics.com/registration-for-12-15-rd-update-webcast/

About the 12^th Annual LifeSci Partners Corporate Access Event

The LifeSci Partners 12th Annual Corporate Access Event will feature more than 200 innovative publicly traded and privately held biotechnology, medical technology, pharmaceutical, life sciences, and digital health companies from across the globe.

This event will include in-person 1×1 meetings with senior management teams to showcase the most relevant topics impacting the life sciences industry today.

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS) and Spinocerebellar ataxia (SCA), as well as early-stage programs in Huntington's disease, Alzheimer's disease, and Parkinson's Disease.

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Forward Looking Statements

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding the topics expected to be discussed at the LifeSci Partners 12th Annual Corporate Access Event, Seelos' ability to complete clinical studies for its product candidates, and Seelos' ability to efficiently execute clinical and pre-clinical programs. These statements are based on Seelos' current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated with Seelos' business include, but are not limited to, the risk of not successfully executing its preclinical and clinical studies, and not gaining marketing approvals for its product candidates, the risk that prior clinical results may not be replicated in future studies and trials, the risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval, the risks associated with the implementation of a new business strategy, the risks related to raising capital to fund its development plans and ongoing operations, risks related to Seelos' current stock price, risks related to the global impact of COVID-19, as well as other factors expressed in Seelos' periodic filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Contact Information:

Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 2^nd Floor
New York, NY 10022
(646) 293-2136
This email address is being protected from spambots. You need JavaScript enabled to view it.
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

Mike Moyer 
Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401 
New York, NY 10019
(617) 308-4306
This email address is being protected from spambots. You need JavaScript enabled to view it.